

CIF A-18.758.300
Avda de la Innovación, n 1
Edificio BIC (Ofic 211)
P. T. de Ciencias de la Salud
18100 Armilla (Granada)
Tel: 958 750 598

Mercado Alternativo Bursátil
Plaza de la Lealtad, 1
28014 Madrid

In Granada, 1 July 2014

RELEVANT FACT OF NEURON BIOPHARMA, S.A.

Dear Sirs,

In compliance with the provisions of the MAB circular 9/2010 on information to be provided by the companies in expansion integrated in the MAB, Neuron Biopharma S.A. (hereinafter "NEURON BIO" or the "Company") hereby informs that:

As reported on 25 May via a relevant fact, yesterday the Neuron Bio General Shareholders' Meeting was going to be held. In the item 5 of the agenda it was foreseen to approve the segregation of the neuroprotective drugs discovery business and the development and diagnostic tools license business. In order to agree validly this point and according to article 18.2 of the Neuron Bio Byelaws, it is required the attendance of shareholders present or represented, on first call, holding at least 50% of the voting capital in order. As the attendance of present or represented shareholders was lower than the 50% of the capital stock there was no sufficient quorum to hold the scheduled General Shareholders' Meeting.

Subsequently the Board of Directors met to fix the second call of the General Shareholders' Meeting. Once the date is published in Spanish Official Companies Registry Bulletin BORME, the market will be informed.

Finally, during this meeting the Board of Directors accepted the resignation submitted by Blanca Clavijo due to personal affairs.

We remain at your disposal for any clarification you consider appropriate.

Kind regards,

Fernando Valdivieso Amate
Chairman of the Board of Directors